

WHAT IS CLAIMED IS:

1. A method for increasing blood platelet formation in a patient in need of said therapy, comprising

administering to said patient an effective amount for said therapy of, as active ingredient, a parathyroid hormone (PTH) or at least one PTH derivative effective for said therapy,

wherein said PTH or PTH derivative is selected from groups (a) to (c):

- (1) a PTH derivative which comprises PTH(1-34), the constituent amino acid(s) of which may be substituted in the 8-position, 16-position and/or 34-position,
- (2) a PTH derivative which is such that one or more of the constituent amino acids of PTH(1-34), the constituent amino acid residue(s) of which may be substituted in the 8-position, 16-position and/or 34-position, are deleted, and
- (3) PTH or a PTH derivative selected from the group consisting of human PTH(1-34), human PTH(1-34)-NH₂, human PTH(1-37), human PTH(1-64), human PTH(1-84), human PTH(35-84) and bovine PTH(1-34).

2. The method according to claim 1 wherein said PTH or PTH derivative is administered along with polyethylene glycol.

3. The method according to claim 1 wherein said PTH or PTH derivative is administered encapsulated within microcapsules.

4. The method according to claim 1 wherein said PTH or PTH derivative is administered in a form incorporated in a sheet of gel.

5. The method according to claim 1 wherein said patient is a patient suffering from thrombocytopenia purpura.

6. The method according to claim 1 wherein said patient is one suffering from selective suppression of megakaryocytes.

7. The method according to claim 6 wherein said patient is a patient who has been or is being treated with at least one of phenylbutazone, gold compounds, tolbutamide and chemotherapeutics.

8. The method according to claim 1 wherein said patient is one suffering from a viral infection.

9. The method according to claim 1 wherein said patient is one suffering from aplastic anemia.

10. The method according to claim 1 wherein said patient is one suffering from osteomyelodysplasia syndrome.

11. The method according to claim 1 wherein said patient is one suffering from leukemia.

12. The method according to claim 1 wherein said patient is one suffering from multiple myeloma.

13. The method of claim 1 wherein said PTH or PTH derivative is selected from the group consisting of human PTH (1-34), human PTH (1-64), human PTH (35-84), bovine PTH (1-34), human PTH (1-84), human PTH (1-38) and human PTH (1-37).

14. The method of claim 13 wherein said PTH or said PTH derivative has at least one of the following substitutions: (1) substitution of leucine or norleucine at the 8-position, (2) substitution of leucine or norleucine at the 18-position, and (3) substitution to tyrosine at the 34-position.

15. The method according to claim 1 wherein said effective amount is in the range of 1 µg to 1,000 µg per kg of body weight systemically at a frequency ranging from once per day to once per month.

16. The method according to claim 1 wherein said effective amount is from 5 μ g to 200 μ g per kg of body weight administered once every two weeks to once daily.

17. The method according to claim 1 wherein the route of said administration is subcutaneously.

18. The method according to claim 1 wherein the route of said administration is intravenously.

19. The method according to claim 1 wherein the route of said administration is intranasally.

20. The method according to claim 1 wherein the route of said administration is transpulmonarily.